For targeting HER2/neu the humanized monoclonal antibody Trastuzumab (Roche, Basel, Switzerland) is legally approved for the treatment of patients with breast cancer and gastric adenocarcinoma that overexpress HER2/neu [23, 24]. This evidence concerns the gene ERBB2 and breast cancer.